Chemotherapy for retinoblastoma.

Détails

ID Serval
serval:BIB_AF0CC5151F73
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Chemotherapy for retinoblastoma.
Périodique
Ophthalmology clinics of North America
Auteur⸱e⸱s
Chan H.S., Gallie B.L., Munier F.L., Beck Popovic M.
ISSN
0896-1549
Statut éditorial
Publié
Date de publication
2005
Volume
18
Numéro
1
Pages
55-63, viii
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review - Publication Status: ppublish
Résumé
Retinoblastoma is the most common eye cancer in children. Pilot studies of chemotherapy for intraocular retinoblastoma have been reported by several groups, using different combinations, dosages, schedules, and durations of carboplatin, etoposide, or teniposide, with or without vincristine, and with or without cyclosporine to counteract multidrug resistance. All studies of chemotherapy for intraocular retinoblastoma have included consolidation by focal therapy, with or without radiation. Chemotherapy alone reduces tumor size but does not cure retinoblastoma. Focal therapy, consisting of photocoagulation, thermotherapy, cryotherapy, or brachytherapy, is necessary to consolidate chemotherapy response.
Mots-clé
Antineoplastic Combined Chemotherapy Protocols, DNA, Neoplasm, Dose-Response Relationship, Drug, Drug Resistance, Multiple, Humans, Neoplasm Recurrence, Local, Neoplasm Staging, Retinal Neoplasms, Retinoblastoma, Treatment Outcome
Pubmed
Création de la notice
20/03/2008 10:34
Dernière modification de la notice
20/08/2019 16:18
Données d'usage